Quanterix Corp represents values of innovation, precision, and dedication to advancing science and healthcare. With a strong corporate philosophy focused on transforming medicine through their proprietary technology, they strive to revolutionize diagnostics and biomarker analysis. Quanterix Corp is committed to developing highly sensitive biomarker detection solutions that enable researchers and clinicians to detect diseases far earlier and more accurately than previously possible. Continuously pushing the boundaries of scientific knowledge, Quanterix Corp's pioneering approach has the potential to improve patient outcomes and revolutionize the way healthcare industry operates.

Quanterix Corp is primarily present in the United States and Europe.

Quanterix Corp has achieved several significant milestones since its inception. The company's groundbreaking Simoa technology has revolutionized the field of ultra-sensitive biomarker analysis, enabling researchers to detect and measure extremely low levels of proteins and biomarkers. Quanterix Corp has also developed a strong portfolio of diagnostic tests for various diseases and conditions, such as neurodegenerative diseases, oncology, and infectious diseases. Moreover, the company has received numerous accolades and recognitions for its innovative approach, including being named a Technology Pioneer by the World Economic Forum. Quanterix Corp continues to advance in its mission to improve healthcare outcomes through cutting-edge diagnostics and precision medicine.

Quanterix Corp is a renowned biotechnology company founded in 2007. With its headquarters in Billerica, Massachusetts, the company specializes in developing ultra-sensitive analysis platforms, known as Simoa, for studying and measuring various biomarkers in life sciences. Quanterix Corp has revolutionized the field of biomarker analysis by enabling detection at previously unattainable levels, enabling breakthroughs in diagnostics, precision medicine, and life sciences research. The company's unparalleled technology has attracted collaborations with prominent academic institutions, pharmaceutical companies, and clinical laboratories worldwide. Quanterix Corp's commitment to innovation and improving patient outcomes has positioned it as a leading player in the field of precision health.

The main competitors of Quanterix Corp in the market are companies like Bio-Techne Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, and Merck KGaA.

Quanterix Corp is primarily active in the life sciences and diagnostics industries.

The business model of Quanterix Corp focuses on developing and commercializing ultra-sensitive biomarker detection systems. By leveraging their proprietary Simoa technology, the company aims to provide researchers and clinicians with the tools necessary to advance precision medicine and improve the detection and treatment of various diseases. Quanterix Corp's cutting-edge platforms enable the measurement of previously undetectable biomarkers, opening up new possibilities in diagnostics, drug development, and personalized healthcare. With their dedication to innovation and pushing the boundaries of detection, Quanterix Corp strives to make a significant impact in the field of life sciences and transform the way diseases are diagnosed and monitored.

Quanterix KGV ir -15,54.

Quanterix KUV ir 3,98.

AlleAktien kvalitātes vērtējums Quanterix ir 4/10.

gaidāmā Quanterix apgrozījums ir 144,93 milj. USD.

gaidāmā Quanterix peļņa ir -37,08 milj. USD.

Quanterix Corp is a company that specializes in the development and sale of instruments and reagents for digital diagnostic applications. It is working on developing technologies that increase the accuracy and sensitivity of tests, enabling better disease diagnosis and monitoring. The company's business model is based on three main divisions: instruments, reagents, and services. They offer automated systems that can conduct biomarker analysis at the single-molecule level. The company also provides training and consulting services for the use of their instruments and reagents. They are known for their Simoa technology, which is used for disease diagnosis based on the measurement of biomarkers in blood. Quanterix Corp works closely with leading companies in the life science industry to integrate their technology into their products. Overall, the company is recognized as a key player in the field of digital diagnostics.

Quanterix izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Quanterix vai uzņēmums nedod dividendes.

Quanterix ISIN ir US74766Q1013.

Quanterix WKN ir A2H9FB.

Quanterix simbols ir QTRX.

Pēdējo 12 mēnešu laikā Quanterix maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Quanterix plāno maksāt dividendes 0 USD apmērā.

Quanterix pašreizējā dividendu rentabilitāte ir .

Quanterix maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Quanterix pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Quanterix tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Quanterix apmērā 0 USD, kas tika izmaksāta 27.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.07.2024..

Pēdējās dividendes izmaksa notika 27.07.2024..

Gadā 2023, Quanterix izmaksāja 0 USD dividendes.

Quanterix dividendes tiek izmaksātas USD.